prIME Symposium on SCCHN and CRC

prIME Symposium on SCCHN and CRC

Applying New Evidence to Patient Care

View Activity

Activity Features

Downloadable Slides

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Activity Overview

View downloadable slides for updates about the latest advances and emerging strategies in the management of squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer (CRC), and how to translate new evidence into clinical practice.

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Featured Expert

  • Cristina Bonorino, PhD, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

Featured Topic

Cancer immunotherapy: Key principles, concepts, and clinical applications

Featured Expert

  • Aline Lauda Freitas Chaves, MD, MBA, MSc, Dom Oncologia, Divinópolis, Brazil

Featured Topic

Locally advanced squamous cell carcinoma of the head and neck (SCCHN): Individualized treatment approach

Featured Expert

  • Raúl E. Giglio, MD, Instituto de Oncologia Angel H Roffo, Buenos Aires, Argentina

Featured Topic

Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond

Featured Expert

  • Kevin Harrington, MBBS, PhD, FRCP, FRCR, Institute of Cancer Research, London, United Kingdom

Featured Topic

Head and neck cancer management in the coming years: What can we expect?

Featured Expert

  • Raúl E. Giglio, MD, Instituto de Oncologia Angel H Roffo, Buenos Aires, Argentina

Featured Topic

prIME Points™

Featured Expert

  • Clara Montagut, MD, PhD, Hospital del Mar, Barcelona, Spain

Featured Topic

Improving outcomes in mCRC: Impact of clinical and molecular markers

Featured Expert

  • André Deeke Sasse, MD, PhD, University of Campinas, Campinas, Brazil

Featured Topic

Metastatic CRC with unresectable liver-only metastases: Multidisciplinary treatment approach

Featured Expert

  • Guillermo Méndez, MD, Hospital de Gastroenterologia Bonorino Udaondo, Buenos Aires, Argentina

Featured Topic

Managing mCRC across the disease continuum: Front-line therapy and treatment beyond progression

Featured Expert

  • Clara Montagut, MD, PhD, Hospital del Mar, Barcelona, Spain

Featured Topic

Colorectal cancer in the coming years: What can we expect?

Featured Expert

  • André Deeke Sasse, MD, PhD, University of Campinas, Campinas, Brazil

Featured Topic

prIME Points™

Target Audience

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons/otolaryngologists, and other healthcare professionals interested and/or involved in the treatment of patients with head & neck cancer and CRC.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe immunotherapeutic principles and the evolving role of immunotherapy for the management of cancer, including SCCHN and metastatic CRC (mCRC)
  • Apply multidisciplinary approaches for managing HPV+ and HPV-, locally advanced SCCHN
  • Identify optimal treatment sequence for patients with recurrent/metastatic SCCHN
  • Explain state-of-the-art management of mCRC, and role of biomarkers to guide personalized therapy
  • Select optimal front-line therapy for individual patients with mCRC, including those with liver-only metastases, and determine best treatment sequence after disease progression

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and Independent Medical Education (IME) performance of learners in order to improve patient care.

Logo_IME_120

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bonorino has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Chaves has disclosed that she received speaking and teaching fees from Bristol-Myers Squibb and Merck Serono. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Giglio has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harrington has disclosed that he received board membership fees from AstraZeneca, Bristol-Myers Squibb, Merck, MSD, and Pfizer. He also received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and MSD. He has received honoraria for promotional speaker’s bureau Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mendez has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Montagut has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sasse has disclosed receipt of fees for consulting and membership on an advisory committee or review panel and speaking and teaching fees from Merck and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships